Olema Pharmaceuticals director files ownership report

Olema Pharmaceuticals, Inc. director Raman Prakash has filed an initial insider ownership report.

Rhea-AI Filing Summary

Olema Pharmaceuticals, Inc. director Raman Prakash has filed an initial insider ownership report. This filing establishes his status as a reporting person for the company and, based on the provided data, does not list any share purchases, sales, or other transactions.

Key Terms

reporting person, insider trading disclosures, derivative securities

3 terms

reporting person regulatory

"This filing establishes his status as a reporting person for the company"

insider trading disclosures regulatory

"his status as a reporting person for the company and future insider trading disclosures"

derivative securities financial

"no listed options, warrants, or other derivative securities for Raman Prakash"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Raman Prakash’s Form 3 mean for Olema Pharmaceuticals (OLMA)?

Raman Prakash’s Form 3 records his status as a director and initial insider ownership report at Olema Pharmaceuticals. It is a routine regulatory step that establishes him as a reporting person for future insider trading disclosures with the SEC.

Does Raman Prakash’s Olema (OLMA) Form 3 show any stock purchases or sales?

The provided Form 3 data for director Raman Prakash shows no reported purchases, sales, or other transactions. All transaction-related counts, including buy, sell, exercise, gift, and tax withholding, appear as zero in the transaction summary section of the filing data.

Why are there no transactions listed for Raman Prakash in this Olema (OLMA) filing?

This filing serves as an initial ownership report, and the structured data shows zero transactions across all categories. Form 3 often functions as a baseline disclosure, with any future insider trades reported later on separate Forms 4 or 5 as required.

What role does Raman Prakash have at Olema Pharmaceuticals (OLMA) in this filing?

In this filing, Raman Prakash is identified as a director of Olema Pharmaceuticals, Inc. The metadata indicates he is not listed as an officer or ten percent owner, so his reporting obligations relate to his board position and any future equity transactions.

Does this Olema (OLMA) Form 3 include any derivative securities for Raman Prakash?

The derivative summary section in the provided data is empty, indicating no listed options, warrants, or other derivative securities for Raman Prakash. Any future grants or derivative holdings would be disclosed in subsequent SEC filings if and when they occur.

How does this Olema Pharmaceuticals (OLMA) filing affect existing shareholders?

This initial ownership filing is mainly administrative and does not change shareholder rights or company fundamentals. It simply records director Raman Prakash as a reporting insider, laying groundwork for transparent disclosure of any future trades involving Olema securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/29/2026 - 04:40 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Raman Prakash

(Last) (First) (Middle)

C/O OLEMA PHARMACEUTICALS, INC.

780 BRANNAN STREET

(Street)

SAN FRANCISCO CALIFORNIA 94103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/28/2026

3. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Shawnte Mitchell, Attorney-in-Fact	04/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)